Loading company…
Ophiomics develops cancer diagnostic and prognostic tests.
Ophiomics combines genomics, AI and bioinformatics to develop tests supporting cancer diagnosis and treatment decisions. Its HepatoPredict product is designed to support liver transplant decisions for hepatocellular carcinoma patients. Founded in 2015, the company is based in Lisbon, Portugal. It raised series A funding led by BlueCrow Capital in January 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in